Trial reportJournal of the American Heart Association2020
Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial.
Trial report in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial.Journal of the American Heart Association · 2020 · on this mapTrial
- Anti-inflammatory agents in atherosclerosis-and a need for reform: Extraordinary claims require extraordinary evidence.Journal of internal medicine · 2026Review
- Short-Term Risk Stratification in Alcohol-Associated Hepatitis: Small HDL Particles and Inflammation Vulnerability Index Values Improve Model for End-Stage Liver Disease.Alcohol, clinical & experimental research · 2026Article
- ABCA1-Mediated Structural Diversity of HDL Subspecies and Their Proposed Roles in Cardioprotection.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- High density lipoproteins and extracellular vesicles-distinct but overlapping circulating particles and their role in atherosclerosis.Frontiers in cardiovascular medicine · 2026Review
- C-reactive protein to high density lipoprotein cholesterol ratio for predicting coronary artery lesions, and intravenous immunoglobulin resistance in Kawasaki disease.Pediatric rheumatology online journal · 2025Article
- Multiple facets of HDLs as modifiable risk factors in stroke-the good, the bad, and the ugly.Journal of lipid research · 2025Review
- Article
- Reduced high-density lipoprotein antioxidant function in patients with coronary artery disease and acute coronary syndrome.JCI insight · 2025Article
- Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?Current atherosclerosis reports · 2025Review
- High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?International journal of molecular sciences · 2025Review
- Analysis of uric acid and high-density lipoprotein levels in refractory posner-schlossman syndrome patients: a matched case-control study by the propensity score.BMC ophthalmology · 2024Article
- High Blood Pressure and Impaired Brain Health: Investigating the Neuroprotective Potential of Magnesium.International journal of molecular sciences · 2024Review
- Development and validation of a machine learning-based readmission risk prediction model for non-ST elevation myocardial infarction patients after percutaneous coronary intervention.Scientific reports · 2024Article
- Article
- Association of non-high-density lipoprotein to high-density lipoprotein ratio (NHHR) with prognosis in cancer survivors: a population-based study in the United States.Frontiers in nutrition · 2024Article
- Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk.Biomedicines · 2023Review
- High-density lipoprotein revisited: biological functions and clinical relevance.European heart journal · 2023Review
- HDL Functions-Current Status and Future Perspectives.Biomolecules · 2023Review
- Dyslipidemia in Transplant Patients: Which Therapy?Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Background High-density lipoprotein (HDL) cholesterol has inverse association with cardiovascular disease. HDL possesses anti-inflammatory properties in vitro, but it is unknown whether this may be protective in individuals with inflammation. Methods and Results The functional capacity of HDL to inhibit oxidation of oxidized low-density lipoprotein (ie, the HDL inflammatory index; HII) was measured at baseline and 12 months after random allocation to rosuvastatin or placebo in a nested case-control study of the JUPITER (Justification for the Use of Statins in Prevention: An Intervention Evaluating Rosuvastatin) trial. There were 517 incident cases of cardiovascular disease and all-cause mortality compared to 517 age- and sex-matched controls. Multivariable conditional logistic regression was used to examine associations of HII with events. Median baseline HII was 0.54 (interquartile range, 0.50-0.59). Twelve months of rosuvastatin decreased HII by a mean of 5.3% (95% CI, -8.9% to -1.7%;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.